$ALXN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ALEXION PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ALEXION PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 ... 22 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Grant | A | 0.00 | 8,250 | 0 | 35,531 | 27.3 K to 35.5 K (+30.24 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Grant | A | 0.00 | 9,428 | 0 | 43,419 | 34 K to 43.4 K (+27.74 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 9,428 | 0 | 40,577 | 31.1 K to 40.6 K (+30.27 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Grant | A | 0.00 | 3,403 | 0 | 7,543 | 4.1 K to 7.5 K (+82.20 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | Chiniara Ellen | EVP & General Couns ... | Grant | A | 0.00 | 8,250 | 0 | 15,961 | 7.7 K to 16 K (+106.99 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Grant | A | 0.00 | 9,428 | 0 | 95,677 | 86.2 K to 95.7 K (+10.93 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | LAW ANNE-MARIE | EVP, Chief Experien ... | Grant | A | 0.00 | 8,839 | 0 | 37,655 | 28.8 K to 37.7 K (+30.67 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | Chief Strategy & Bu ... | Payment of Exercise | F | 132.92 | 267 | 35,490 | 22,529 | 22.8 K to 22.5 K (-1.17 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | Chiniara Ellen | EVP & General Couns ... | Payment of Exercise | F | 132.92 | 633 | 84,138 | 7,711 | 8.3 K to 7.7 K (-7.59 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 93.01 | 34 | 3,162 | 31,149 | 31.1 K to 31.1 K (+0.11 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 132.92 | 675 | 89,721 | 31,115 | 31.8 K to 31.1 K (-2.12 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | LAW ANNE-MARIE | EVP, Chief Experien ... | Payment of Exercise | F | 132.93 | 634 | 84,278 | 28,816 | 29.5 K to 28.8 K (-2.15 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Payment of Exercise | F | 132.92 | 4,043 | 537,396 | 133,638 | 137.7 K to 133.6 K (-2.94 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Payment of Exercise | F | 132.93 | 1,079 | 143,431 | 86,249 | 87.3 K to 86.2 K (-1.24 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Payment of Exercise | F | 132.93 | 670 | 89,063 | 33,991 | 34.7 K to 34 K (-1.93 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Payment of Exercise | F | 132.93 | 625 | 83,081 | 27,281 | 27.9 K to 27.3 K (-2.24 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 132.92 | 381 | 50,643 | 4,140 | 4.5 K to 4.1 K (-8.43 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 132.92 | 216 | 28,711 | 4,521 | 4.7 K to 4.5 K (-4.56 %) |
Mar 01 2019 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 135.58 | 70 | 9,491 | 4,737 | 4.8 K to 4.7 K (-1.46 %) |
Feb 28 2019 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 132.49 | 213 | 28,220 | 4,807 | 5 K to 4.8 K (-4.24 %) |
Feb 19 2019 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Sell | S | 126.00 | 2,000 | 252,000 | 5,020 | 7 K to 5 K (-28.49 %) |
Feb 11 2019 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Payment of Exercise | F | 119.57 | 13,015 | 1,556,204 | 137,681 | 150.7 K to 137.7 K (-8.64 %) |
Feb 11 2019 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Payment of Exercise | F | 119.57 | 5,981 | 715,148 | 87,328 | 93.3 K to 87.3 K (-6.41 %) |
Feb 11 2019 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Payment of Exercise | F | 119.57 | 1,596 | 190,834 | 34,661 | 36.3 K to 34.7 K (-4.40 %) |
Feb 11 2019 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Payment of Exercise | F | 119.57 | 1,398 | 167,159 | 27,906 | 29.3 K to 27.9 K (-4.77 %) |
Nov 30 2018 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Sell | S | 118.13 | 2,605 | 307,729 | 29,304 | 31.9 K to 29.3 K (-8.16 %) |
Jul 12 2018 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Sell | S | 131.11 | 5,241 | 687,148 | 93,309 | 98.6 K to 93.3 K (-5.32 %) |
Jun 12 2018 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Sell | S | 118.53 | 1,466 | 173,765 | 31,909 | 33.4 K to 31.9 K (-4.39 %) |
Jun 12 2018 | ALXN | ALEXION PHARMACEUT ... | LAW ANNE-MARIE | EVP and CHRO | Sell | S | 118.53 | 1,862 | 220,703 | 29,450 | 31.3 K to 29.5 K (-5.95 %) |
Jun 12 2018 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Sell | S | 118.53 | 1,645 | 194,982 | 36,257 | 37.9 K to 36.3 K (-4.34 %) |
Jun 12 2018 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Sell | S | 118.53 | 2,115 | 250,691 | 31,790 | 33.9 K to 31.8 K (-6.24 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 2,174 | 0 | 7,648,080 | 7.6 M to 7.6 M (+0.03 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 2,174 | 0 | 982,320 | 980.1 K to 982.3 K (+0.22 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | Reinsdorf Judith A | Director | Grant | A | 0.00 | 2,174 | 0 | 4,259 | 2.1 K to 4.3 K (+104.27 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 0.00 | 2,174 | 0 | 28,507 | 26.3 K to 28.5 K (+8.26 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | Dunsire Deborah | Director | Grant | A | 0.00 | 2,174 | 0 | 4,259 | 2.1 K to 4.3 K (+104.27 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Grant | A | 0.00 | 2,174 | 0 | 19,420 | 17.2 K to 19.4 K (+12.61 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | Nader Francois | Director | Grant | A | 0.00 | 2,174 | 0 | 4,151 | 2 K to 4.2 K (+109.96 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | Mollen John T | Director | Grant | A | 0.00 | 2,174 | 0 | 6,507 | 4.3 K to 6.5 K (+50.17 %) |
May 11 2018 | ALXN | ALEXION PHARMACEUT ... | FRIEDMAN PAUL A | Director | Grant | A | 0.00 | 2,174 | 0 | 4,151 | 2 K to 4.2 K (+109.96 %) |
May 02 2018 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Buy | P | 120.79 | 10,000 | 1,207,900 | 26,333 | 16.3 K to 26.3 K (+61.23 %) |
Mar 02 2018 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 8,940 | 0 | 33,905 | 25 K to 33.9 K (+35.81 %) |
Mar 02 2018 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Grant | A | 0.00 | 8,940 | 0 | 37,902 | 29 K to 37.9 K (+30.87 %) |
Mar 02 2018 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Grant | A | 0.00 | 8,940 | 0 | 51,727 | 42.8 K to 51.7 K (+20.89 %) |
Mar 01 2018 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 118.61 | 686 | 81,366 | 42,787 | 43.5 K to 42.8 K (-1.58 %) |
Mar 01 2018 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 120.72 | 939 | 113,356 | 43,473 | 44.4 K to 43.5 K (-2.11 %) |
Mar 01 2018 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 118.61 | 454 | 53,849 | 49,140 | 49.6 K to 49.1 K (-0.92 %) |
Mar 01 2018 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 120.72 | 244 | 29,456 | 49,594 | 49.8 K to 49.6 K (-0.49 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Sell | S | 116.31 | 1,651 | 192,028 | 28,962 | 30.6 K to 29 K (-5.39 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Grant | A | 0.00 | 15,894 | 0 | 30,613 | 14.7 K to 30.6 K (+107.98 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 116.31 | 1,774 | 206,334 | 49,838 | 51.6 K to 49.8 K (-3.44 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Grant | A | 0.00 | 4,400 | 0 | 51,612 | 47.2 K to 51.6 K (+9.32 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Grant | A | 0.00 | 14,577 | 0 | 47,212 | 32.6 K to 47.2 K (+44.67 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Sell | S | 116.31 | 6,079 | 707,048 | 89,014 | 95.1 K to 89 K (-6.39 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Grant | A | 0.00 | 48,228 | 0 | 95,093 | 46.9 K to 95.1 K (+102.91 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Sell | S | 116.31 | 1,459 | 169,696 | 25,031 | 26.5 K to 25 K (-5.51 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Grant | A | 0.00 | 13,908 | 0 | 26,490 | 12.6 K to 26.5 K (+110.54 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 116.31 | 4,787 | 556,776 | 44,412 | 49.2 K to 44.4 K (-9.73 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Grant | A | 0.00 | 7,500 | 0 | 49,199 | 41.7 K to 49.2 K (+17.99 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Grant | A | 0.00 | 21,489 | 0 | 41,699 | 20.2 K to 41.7 K (+106.33 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 115.70 | 1,200 | 138,840 | 74,537 | 75.7 K to 74.5 K (-1.58 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 115.70 | 2,163 | 250,259 | 75,737 | 77.9 K to 75.7 K (-2.78 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Grant | A | 0.00 | 6,500 | 0 | 77,900 | 71.4 K to 77.9 K (+9.10 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Grant | A | 0.00 | 21,489 | 0 | 71,400 | 49.9 K to 71.4 K (+43.05 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Sell | S | 116.31 | 13,245 | 1,540,526 | 118,180 | 131.4 K to 118.2 K (-10.08 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Grant | A | 0.00 | 95,253 | 0 | 131,425 | 36.2 K to 131.4 K (+263.33 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Reinsdorf Judith A | Director | Grant | A | 0.00 | 2,085 | 0 | 2,085 | 0 to 2.1 K |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Dunsire Deborah | Director | Grant | A | 0.00 | 2,085 | 0 | 2,085 | 0 to 2.1 K |
Feb 07 2018 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 117.26 | 655 | 76,805 | 32,635 | 33.3 K to 32.6 K (-1.97 %) |
Feb 07 2018 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 117.26 | 1,261 | 147,865 | 49,911 | 51.2 K to 49.9 K (-2.46 %) |
Feb 07 2018 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 117.26 | 2,119 | 248,474 | 20,210 | 22.3 K to 20.2 K (-9.49 %) |
Jan 04 2018 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Sell | S | 121.63 | 2,553 | 310,521 | 36,172 | 38.7 K to 36.2 K (-6.59 %) |
Dec 05 2017 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 112.75 | 10,000 | 1,127,500 | 16,333 | 6.3 K to 16.3 K (+157.90 %) |
Nov 30 2017 | ALXN | ALEXION PHARMACEUT ... | FRIEDMAN PAUL A | Director | Grant | A | 0.00 | 1,977 | 0 | 1,977 | 0 to 2 K |
Nov 30 2017 | ALXN | ALEXION PHARMACEUT ... | Nader Francois | Director | Grant | A | 0.00 | 1,977 | 0 | 1,977 | 0 to 2 K |
Oct 04 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 140.00 | 120 | 16,800 | 33,290 | 33.4 K to 33.3 K (-0.36 %) |
Sep 05 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 145.81 | 650 | 94,777 | 22,329 | 23 K to 22.3 K (-2.83 %) |
Sep 05 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 145.64 | 600 | 87,384 | 22,979 | 23.6 K to 23 K (-2.54 %) |
Sep 05 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 147.00 | 672 | 98,784 | 23,579 | 24.3 K to 23.6 K (-2.77 %) |
Sep 05 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 145.81 | 1,841 | 268,436 | 24,251 | 26.1 K to 24.3 K (-7.06 %) |
Sep 05 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 142.00 | 612 | 86,904 | 26,092 | 26.7 K to 26.1 K (-2.29 %) |
Sep 05 2017 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Sell | S | 145.81 | 835 | 121,751 | 5,480 | 6.3 K to 5.5 K (-13.22 %) |
Aug 30 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 140.00 | 11,160 | 1,562,400 | 26,704 | 37.9 K to 26.7 K (-29.47 %) |
Aug 02 2017 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Sell | S | 137.74 | 700 | 96,418 | 6,315 | 7 K to 6.3 K (-9.98 %) |
Jul 12 2017 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Option Exercise | A | 123.76 | 29,089 | 3,600,055 | 29,089 | |
Jul 12 2017 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Grant | A | 0.00 | 46,865 | 0 | 46,865 | 0 to 46.9 K |
Jun 19 2017 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Buy | P | 116.72 | 10,000 | 1,167,200 | 38,725 | 28.7 K to 38.7 K (+34.81 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Buy | P | 117.10 | 2,000 | 234,200 | 6,333 | 4.3 K to 6.3 K (+46.16 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 116.78 | 835 | 97,511 | 7,568 | 8.4 K to 7.6 K (-9.94 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.95 | 22,560 | 2,660,914 | 7,317,906 | 7.3 M to 7.3 M (+0.31 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.95 | 2,564 | 302,419 | 647,367 | 644.8 K to 647.4 K (+0.40 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.51 | 197,126 | 23,163,488 | 7,295,346 | 7.1 M to 7.3 M (+2.78 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.51 | 22,399 | 2,632,017 | 644,803 | 622.4 K to 644.8 K (+3.60 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.22 | 32,172 | 3,771,228 | 7,098,220 | 7.1 M to 7.1 M (+0.46 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.22 | 3,656 | 428,559 | 622,404 | 618.7 K to 622.4 K (+0.59 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.01 | 65,264 | 7,636,802 | 7,066,048 | 7 M to 7.1 M (+0.93 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.01 | 7,416 | 867,776 | 618,748 | 611.3 K to 618.7 K (+1.21 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.96 | 898 | 105,030 | 7,000,784 | 7 M to 7 M (+0.01 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.96 | 102 | 11,930 | 611,332 | 611.2 K to 611.3 K (+0.02 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.71 | 31,974 | 3,731,542 | 6,999,886 | 7 M to 7 M (+0.46 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.71 | 3,634 | 424,108 | 611,230 | 607.6 K to 611.2 K (+0.60 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.37 | 12,726 | 1,480,897 | 6,967,912 | 7 M to 7 M (+0.18 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.37 | 1,446 | 168,268 | 607,596 | 606.2 K to 607.6 K (+0.24 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.37 | 385,774 | 44,891,517 | 6,955,186 | 6.6 M to 7 M (+5.87 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.37 | 43,835 | 5,100,965 | 606,150 | 562.3 K to 606.2 K (+7.80 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.18 | 1,976 | 229,562 | 6,569,412 | 6.6 M to 6.6 M (+0.03 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.18 | 224 | 26,023 | 562,315 | 562.1 K to 562.3 K (+0.04 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.77 | 169,897 | 19,668,568 | 6,567,436 | 6.4 M to 6.6 M (+2.66 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.77 | 19,305 | 2,234,894 | 562,091 | 542.8 K to 562.1 K (+3.56 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.71 | 207,814 | 24,046,636 | 6,397,539 | 6.2 M to 6.4 M (+3.36 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.71 | 23,614 | 2,732,430 | 542,786 | 519.2 K to 542.8 K (+4.55 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.06 | 18,678 | 2,149,048 | 6,189,725 | 6.2 M to 6.2 M (+0.30 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.06 | 2,122 | 244,152 | 519,172 | 517.1 K to 519.2 K (+0.41 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 114.33 | 64,455 | 7,369,301 | 6,171,047 | 6.1 M to 6.2 M (+1.06 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 114.33 | 7,324 | 837,371 | 517,050 | 509.7 K to 517.1 K (+1.44 %) |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Option Exercise | A | 100.14 | 21,750 | 2,178,045 | 21,750 | |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Grant | A | 0.00 | 14,719 | 0 | 14,719 | 0 to 14.7 K |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Option Exercise | A | 100.14 | 25,165 | 2,520,023 | 25,165 | |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Grant | A | 0.00 | 12,582 | 0 | 12,582 | 0 to 12.6 K |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | LAW ANNE-MARIE | EVP and CHRO | Grant | A | 0.00 | 22,968 | 0 | 0 | -22,968 to 0 (-100.00 %) |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 24,965 | 0 | 24,965 | 0 to 25 K |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Grant | A | 0.00 | 2,030 | 0 | 8,403 | 6.4 K to 8.4 K (+31.85 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Grant | A | 0.00 | 2,030 | 0 | 17,246 | 15.2 K to 17.2 K (+13.34 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | BURNS M MICHELE | Director | Grant | A | 0.00 | 2,030 | 0 | 4,353 | 2.3 K to 4.4 K (+87.39 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Grant | A | 0.00 | 2,030 | 0 | 4,906 | 2.9 K to 4.9 K (+70.58 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Grant | A | 0.00 | 2,030 | 0 | 7,015 | 5 K to 7 K (+40.72 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 0.00 | 2,030 | 0 | 4,333 | 2.3 K to 4.3 K (+88.15 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Grant | A | 0.00 | 2,030 | 0 | 4,833 | 2.8 K to 4.8 K (+72.42 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | Mollen John T | Director | Grant | A | 0.00 | 2,030 | 0 | 4,333 | 2.3 K to 4.3 K (+88.15 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 2,030 | 0 | 6,106,592 | 6.1 M to 6.1 M (+0.03 %) |
May 12 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 2,030 | 0 | 509,726 | 507.7 K to 509.7 K (+0.40 %) |
Mar 29 2017 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Option Exercise | A | 118.83 | 56,762 | 6,745,028 | 56,762 | |
Mar 29 2017 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Grant | A | 0.00 | 28,725 | 0 | 57,450 | 28.7 K to 57.5 K (+100.00 %) |
Mar 06 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 131.01 | 3,783 | 495,611 | 33,860 | 37.6 K to 33.9 K (-10.05 %) |
Mar 06 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 133.80 | 651 | 87,104 | 37,864 | 38.5 K to 37.9 K (-1.69 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Option Exercise | A | 131.25 | 12,800 | 1,680,000 | 12,800 | |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Grant | A | 0.00 | 6,500 | 0 | 51,172 | 44.7 K to 51.2 K (+14.55 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 132.50 | 282 | 37,365 | 44,672 | 45 K to 44.7 K (-0.63 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 131.71 | 910 | 119,856 | 44,954 | 45.9 K to 45 K (-1.98 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 131.20 | 612 | 80,294 | 45,864 | 46.5 K to 45.9 K (-1.32 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Option Exercise | A | 131.25 | 14,800 | 1,942,500 | 14,800 | |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Grant | A | 0.00 | 7,500 | 0 | 38,515 | 31 K to 38.5 K (+24.18 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 131.70 | 664 | 87,449 | 31,015 | 31.7 K to 31 K (-2.10 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 131.20 | 910 | 119,392 | 31,679 | 32.6 K to 31.7 K (-2.79 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Option Exercise | A | 131.25 | 8,700 | 1,141,875 | 8,700 | |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Grant | A | 0.00 | 4,400 | 0 | 19,284 | 14.9 K to 19.3 K (+29.56 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 131.70 | 330 | 43,461 | 14,884 | 15.2 K to 14.9 K (-2.17 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 131.20 | 260 | 34,112 | 15,214 | 15.5 K to 15.2 K (-1.68 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Option Exercise | A | 131.25 | 12,800 | 1,680,000 | 12,800 | |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 132.50 | 370 | 49,025 | 50,688 | 51.1 K to 50.7 K (-0.72 %) |